Mycobacterium abscessus pulmonary infection treated with tigecyclin-amikacin and cefoxitin in a diabetic patient;Infection pulmonaire à Mycobacterium abscessus chez une patiente diabétique traitée par l'association tigécyclineamikacine- céfoxitime

Medecine et Maladies Infectieuses

Volumn 41, Issue 8, 2011, Pages 446-448

  Prevotat, A ^a   Bonne, S ^a   Veziris, N ^b,c   Senneville, E ^a   Yazdanpanah, Y ^a   Legout, L ^a  

^a CENTRE HOSPITALIER DE TOURCOING   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Centre National de Référence de la Resistance des Mycobacteries aux Antituberculeux   (France)

Author keywords

Clarithromycin; Mycobacterium abscessus; Tigecyclin

Indexed keywords

AMIKACIN; CEFOXITIN; TIGECYCLINE;

BRONCHIECTASIS; DIABETES MELLITUS; DIABETIC PATIENT; HUMAN; LETTER; LUNG INFECTION; LUNG LAVAGE; LYMPHOCYTE; MYCOBACTERIUM ABSCESSUS; PNEUMONIA;

AMIKACIN; ANTI-BACTERIAL AGENTS; CEFOXITIN; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG DISEASES; MIDDLE AGED; MINOCYCLINE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS;

EID: 79961022887     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.02.011     Document Type: Letter

References (7)

1. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367-416.
2. Nash K.A., Brown-Elliott B.A., Wallace R.J. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009, 53(4):1367-1376.
3. Nash K.A., Andini N., Zhang Y., Brown-Elliott B.A., Wallace R.J. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother 2006, 50(10):3476-3478.
4. Wallace R.J., Brown-Elliott B.A., Ward S.C., Crist C.J., Mann L.B., Wilson R.W. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001, 45(3):764-767.
5. Wallace R.J., Brown-Elliott B.A., Crist C.J., Mann L., Wilson R.W. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002, 46(10):3164-3167.
6. Fernandez-Roblas R., Martin-de-Hijas N.Z., Fernandez-Martinez A.I., Garcia-Almeida D., Gadea I., Esteban J. In vitro activities of tigecycline and 10 other antimicrobials against non-pigmented rapidly growing mycobacteria. Antimicrob Agents Chemother 2008, 52(11):4184-4186.
7. Fernandez-Roblas R., Esteban J., Cabria F., Lopez J.C., Jimenez M.S., Soriano F. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. Antimicrob Agents Chemother 2000, 44(1):181-182.